All News

Muhammad Umair Mushtaq, MD, discussed the evolution of TIL therapy in melanoma, focusing on first-line treatment potential and immune fitness.

Grade 3 or higher TRAEs occurred in 14% of patients treated with NDI-101150, including 1 incidence of grade 4 aplastic anemia across all comers in the study.

The FDA has granted RMAT designation to RZ-001, a first-in-class RNA trans-splicing ribozyme gene therapy, for the management of hepatocellular carcinoma.

Experts highlight advances in cellular therapies that were discussed at the 2026 National ICE-T Conference in Charlotte, North Carolina.

Jennifer Effie Amengual, MD, detailed a clinical trial evaluating the dual epigenetic combination of tazemetostat and belinostat for the treatment of T-cell lymphomas.

The FDA has approved zenocutuzumab for the treatment of patients with NRG1 fusion-positive cholangiocarcinoma after progression on or after systemic therapy.

Data from the phase 1/2 RMC-6236-001 trial show that the RAS(ON) multiselective inhibitor daraxonrasib yielded responses in pretreated RAS-mutated PDAC.

Ralph V. Boccia, MD, FACP, discussed the operational hurdles of administering bispecific antibodies in community settings.

Jennifer Effie Amengual, MD, discussed using epigenetic drugs to enhance immune surveillance and other novel lymphoma therapeutic strategies.

Mohamed Adam, MD, discusses switching from open to robotic Whipple procedures and the impending integration of AI-driven navigation in surgical oncology.

The FDA has set a Prescription Drug User Fee Act date of January 4, 2027, for approving taletrectinib in this ROS1-positive NSCLC population.

There are reimbursement and infrastructure challenges in oncology care, with the need for systemic changes to provide patients with lifesaving behavioral interventions.

Novel bispecifics may bridge gaps in care, especially among patients in rural settings, according to Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA.

Using T-cell–redirecting therapies in less heavily pretreated populations may be a beneficial space to capitalize on, said Barry Paul, MD.

The FDA’s decision is based on data from the phase 1/2 eNRGy trial, which demonstrated that zenocutuzumab yielded responses in NRG1+ cholangiocarcinoma.

Clearance of a novel AI platform may represent an important advance in personalizing treatments for patients with early-stage breast cancer.

The ASPHO Conference brings together the world’s leading experts in pediatric oncology and hematology, and this collection of posters detail new findings in care.

ASCO has recommended expanded eligibility for independent oncology practices and stricter oversight to ensure savings benefit for underserved patients.

Investigators are on track to complete the phase 1b dose-escalation portion of the RAINIER trial in 2026.